Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Gains from Sales and Divestitures (2022 - 2026)

Oric Pharmaceuticals filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $5216.0 for Q1 2026.

  • Quarterly Gains from Sales and Divestitures rose 43.02% to $5216.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5216.0 through Mar 2026, up 43.02% year-over-year, with the annual reading at $395252.0 for FY2025, 28.81% up from the prior year.
  • Gains from Sales and Divestitures hit $5216.0 in Q1 2026 for Oric Pharmaceuticals, down from $395252.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $395252.0 in Q4 2025 and bottomed at $1662.0 in Q1 2023.
  • Average Gains from Sales and Divestitures over 5 years is $77048.6, with a median of $15695.5 recorded in 2024.
  • The largest annual shift saw Gains from Sales and Divestitures surged 172.59% in 2023 before it increased 12.39% in 2025.
  • Oric Pharmaceuticals' Gains from Sales and Divestitures stood at $66811.0 in 2022, then surged by 172.59% to $182122.0 in 2023, then skyrocketed by 68.49% to $306850.0 in 2024, then grew by 28.81% to $395252.0 in 2025, then tumbled by 98.68% to $5216.0 in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Gains from Sales and Divestitures are $5216.0 (Q1 2026), $395252.0 (Q4 2025), and $37770.0 (Q3 2025).